Several agents are being used in clinical trials and compassionate-use protocols based on in vitro activity against SARS-CoV-2 or related viruses, and on limited clinical experience [3]. Early detection and optimized supportive care to relieve symptoms and support organ function in more severe presentations are the mainstay of management. Where possible, moderate to severely ill patients should be managed in a hospital setting [4].
There are hundreds of clinical protocols around the world adapted locally to patient characteristics, prevention measures, diagnostic tests, avai